ReviewNeuropharmacology2022
Cannabidiol and substance use disorder: Dream or reality.
Review in Neuropharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
"Randomized Double-blind Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of the Use of Cannabis Sativa Extract in the Treatment of Cocaine and Crack Addicts."
Evaluating the Efficacy of Cannabidiol for Reducing Cigarette Use
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Efficacy of cannabidiol alone or in combination with Δ-9-tetrahydrocannabinol for the management of substance use disorders: An umbrella review of the evidence.Addiction (Abingdon, England) · 2025Pooled it
- Cannabidiol as a treatment for cocaine use disorder: a scoping review.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Effect of cannabinol, tetrahydrocannabivarin and cannabidiol on voluntary alcohol consumption.Alcohol and alcoholism (Oxford, Oxfordshire) · 2026Article
- Cannabis Use Characteristics and Reasons for Product Choices Among Patients Accessing Treatment for Substance Use Disorders: A Mixed-Methods Study.Cannabis (Albuquerque, N.M.) · 2025Article
- The Development of Cannabinoids as Therapeutic Agents in the United States.Pharmacological reviews · 2024Review
- Identification of the circRNA-miRNA-mRNA network for treating methamphetamine-induced relapse and behavioral sensitization with cannabidiol.CNS neuroscience & therapeutics · 2024Article
- Promising immunomodulators for management of substance and alcohol use disorders.Expert opinion on pharmacotherapy · 2024Review
- The Therapeutic Potential of Cannabidiol in Revolutionising Opioid Use Disorder Management.Cureus · 2023Review
- Cannabidiol as a Harm Reduction Strategy for People Who Use Drugs: A Rapid Review.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2023Review
- Risk assessment of substance use disorders based on the human leukocyte antigen (HLA).Scientific reports · 2023Article
- Cannabidiol-Loaded Nanocarriers and Their Therapeutic Applications.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Advances in mitophagy and mitochondrial apoptosis pathway-related drugs in glioblastoma treatment.Frontiers in pharmacology · 2023Review
- Identification of key genes and therapeutic drugs for cocaine addiction using integrated bioinformatics analysis.Frontiers in neuroscience · 2023Article
- The neuroprotective effects of targeting key factors of neuronal cell death in neurodegenerative diseases: The role of ER stress, oxidative stress, and neuroinflammation.Frontiers in cellular neuroscience · 2023Review
- In utero exposure to cannabidiol disrupts select early-life behaviors in a sex-specific manner.Translational psychiatry · 2022Article
- Sex Differences in the Neuropsychiatric Effects and Pharmacokinetics of Cannabidiol: A Scoping Review.Biomolecules · 2022Article
- Cannabidiol Use Among Older Adults: Associations with Cannabis Use, Physical and Mental Health, and Other Substance Use.Clinical gerontologistArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundCannabidiol (CBD) is one of the major constituents of Cannabis sativa L. that lacks psychotomimetic and rewarding properties and inhibits the rewarding and reinforcing effects of addictive drugs such as cocaine, methamphetamine (METH), and morphine. Additionally, CBD's safety profile and therapeutic potential are currently evaluated in several medical conditions, including pain, depression, movement disorders, epilepsy, multiple sclerosis, Alzheimer's disease, ischemia, and substance use disorder. There is no effective treatment for substance use disorders such as addiction, and this review aims to describe preclinical and clinical investigations into the effects of CBD in various models of opioid, psychostimulant, cannabis, alcohol, and nicotine abuse. Furthermore, the possible mechanisms underlying the therapeutic potential of CBD on drug abuse disorders are reviewed.
methodsThe current review considers and summarizes the preclinical and clinical investigations into CBD's effects in various models of drug abuse include opioids, psychostimulants, cannabis, alcohol, and nicotine.
resultsSeveral preclinical and clinical studies have proposed that CBD may be a reliable agent to inhibit the reinforcing and rewarding impact of drugs.
conclusionsWhile the currently available evidence converges to suggest that CBD could effectively reduce the rewarding and reinforcing effects of addictive drugs, more preclinical and clinical studies are needed before CBD can be added to the therapeutic arsenal for treating addiction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.